TLDR
- Hims & Hers (HIMS) shares jumped approximately 13% on April 16, 2026, after FDA peptide regulatory announcements
- FDA announced advisory committee sessions set for July 23-24 to review multiple peptides for potential 503A Bulks List addition
- Bank of America Securities increased its price objective to $25 from $21, maintaining its Neutral stance
- Analysts view this development as modestly positive for the long term, though near-term earnings projections remain unchanged
- Company insiders have offloaded roughly $3.4 million in shares over the last quarter, with no insider buying activity
Shares of Hims & Hers Health (HIMS) experienced a significant rally, climbing as high as 13.72% during trading on April 16, 2026. The surge came after the FDA revealed plans to convene advisory committee sessions to assess various wellness peptides that remain under restricted status according to current regulatory guidelines.
Hims & Hers Health, Inc., HIMS
The regulatory agency released a formal notice announcing Pharmacy Compounding Advisory Committee sessions scheduled for July 23 and 24. During these meetings, officials will evaluate multiple peptide-related bulk drug compounds for potential addition to the 503A Bulks List. This represents an initial procedural milestone rather than outright regulatory approval.
Investor sentiment received an additional boost from RFK Jr.’s public statements regarding possible shifts in FDA regulatory policy. The agency is considering removing restrictions on as many as 12 different peptides, with evaluation proceedings extending through February 2027.
The telehealth company’s shares had already demonstrated strong momentum prior to this announcement. Data from InvestingPro indicates that HIMS gained approximately 25% over the preceding week.
Bank of America Increases Price Objective
In response to the regulatory development, BofA Securities elevated its price target for HIMS to $25 from the previous $21 level, though the firm maintained its Neutral investment rating. The adjustment reflects an increased valuation multiple of roughly 25.5 times compared to the earlier 21.5 times, driven by higher peer group multiples and emerging peptide opportunities.
Analysts at BofA highlighted that this regulatory shift could enable the company to redirect its established GLP-1 compounding infrastructure toward alternative peptide products. This possibility carries significance given that HIMS has already invested substantially in GLP-1 infrastructure before facing earlier FDA compounding limitations.
The investment firm emphasized a cautious perspective on the announcement. Analysts characterized the news as “an initial small step” and indicated they anticipate no immediate effect on earnings projections unless the FDA proceeds with an official determination.
The regulatory agency also emphasized that the majority of compounds under consideration continue to present potential safety concerns according to existing guidance frameworks.
Recent Developments at HIMS
The telemedicine platform recently expanded its offerings to include Novo Nordisk’s FDA-authorized GLP-1 treatments, featuring Wegovy in both injectable and oral formulations. The oral version of Wegovy represents the sole FDA-cleared GLP-1 weight management pill on the market.
Additionally, the platform now provides access to Ozempic injection pens, though these products carry approval exclusively for Type 2 diabetes management.
The GLP-1 market landscape has become increasingly competitive. Amazon Pharmacy recently launched availability of Eli Lilly’s newly approved GLP-1 medication Foundayo with same-day delivery options, intensifying competitive pressure on both Novo Nordisk and HIMS.
Regarding insider transactions, Chief Financial Officer Oluyemi Okupe submitted documentation to divest shares valued at approximately $4.9 million. Throughout the past quarter, company insiders have collectively sold roughly $3.4 million worth of stock, while no insider purchase activity has been documented.
HIMS currently trades at a price-to-earnings multiple in the 45-47x range. According to InvestingPro’s valuation analysis, the shares appear overvalued compared to Fair Value calculations. The telehealth company carries a market capitalization of approximately $5.54 billion and serves more than 2 million subscribers.
BofA’s EBITDA projection for 2026 stands roughly 21% beneath the Wall Street consensus forecast, a discrepancy the firm has previously highlighted in earlier research communications.
